The global biopsy devices market is projected to reach USD 12.6 billion by 2028 from USD 6.6 billion in 2023, at a CAGR of 14.0% from 2023 to 2028. Advancements in medical technology have led to the development of more precise and minimally invasive biopsy tools, reducing patient discomfort and recovery times. Secondly, an aging global population has increased the demand for cancer screening and diagnosis, where biopsies play a crucial role. Additionally, the rising incidence of cancer and other chronic diseases has spurred the need for more frequent and accurate tissue sampling.
The biopsy devices market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2022, the key player operating in the global biopsy devices market are Becton, Dickinson and Company (US), Devicor Medical Products, Inc., (Leica Biosystems) (US), B. Braun Melsungen AG (Germany), Hologic, Inc. (US), and Cardinal Health, Inc. (US) among others.
To know about the assumptions considered for the study download the pdf brochure
The key strategies adopted by the top players in this market in the last four years include product launches & expansions, partnerships, acquisitions, and collaborations. In 2022, a major share of the Biopsy devices market was held by Becton, Dickinson and Company (US), Devicor Medical Products, Inc., (Leica Biosystems) (US), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (US)
Becton, Dickinson and Company (US)
BD (US) commanded the largest share of 28.0% of the global biopsy devices market in 2022. This company operates through two business segments, BD Medical and BD Life Sciences. BD operates in North America, Europe, EMA (which includes the Commonwealth of Independent States, the Middle East, and Africa), APAC, and Latin America. The company mainly focuses on inorganic growth strategies like acquisitions and agreements.
Devicor Medical Products, Inc. (A Part Of Leica Biosystems) (US)
Devicor Medical Products' "right to win" is grounded in its commitment to innovation, offering a portfolio of cutting-edge medical devices such as advanced breast biopsy systems and tissue markers. With a strong focus on regulatory compliance, clinical validation, and a global market presence, the company ensures the safety and efficacy of its products while fostering customer confidence. Leveraging strategic partnerships, a customer-centric approach, and a dedication to sustainability, Devicor maintains a robust brand reputation and operational efficiency. Its continuous improvement efforts, financial stability, and a talented workforce further solidify its competitive advantage, enabling the company to excel in the dynamic field of medical device manufacturing and breast care solutions.
Cardinal Health. (US)
Cardinal Health's competitive advantage in its medical segment is based on its strong market position, extensive distribution network, diverse and high-quality product portfolio, efficient supply chain management, and robust customer relationships with healthcare providers. The company's commitment to quality assurance, compliance with regulatory standards, and investments in innovation and technology also contribute to its ability to succeed in the medical industry. By offering excellent customer service, managing costs effectively, and staying attuned to market trends, Cardinal Health maintains a competitive edge in a dynamic and evolving healthcare landscape.
Biopsy Devices Market by Product (Gun, Needle, Forcep, VAB, CNB, Liquid Biopsy, Localization wire), Application (Breast, Lung, Prostate) Guidance (Ultrasound, MRI, NGS, PCR), End User (Hospitals, Clinics) & Buying Criteria - Global Forecasts to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE